Autogynephilia:The Study Activists Wanted Buried - Dr. Ray Blanchard (#41)
3 October 2025
With Ray Blanchard
Global
Dr. Ray Blanchard's 1989 peer-reviewed typology of male-to-female transsexualism proposed autogynephilia — erotic arousal at the image of oneself as female — as a distinct clinical pathway. The concept gained empirical support yet was aggressively marginalised by activist pressure inside clinical institutions. This episode asks what science loses when ideological conformity overrides evidence, a question with direct implications for the clinical guidelines and safeguarding standards that European health systems are now being asked to rebuild.
Dr. Ray Blanchard built his research career inside a gender identity clinic, working directly with patients over fifteen years before drawing the theoretical conclusions that would make his name controversial. That clinical grounding gave his work an empirical specificity that distinguished it from the more speculative writing that characterised much of the field. His 1989 paper introduced a systematic typology of male-to-female transsexualism — the kind of careful, patient-based taxonomy that gender medicine urgently needed and has since struggled to apply. The concept at the centre of his framework was autogynephilia: a male's erotic arousal at the thought or image of himself as a woman, as distinct from attraction to other women or to cross-dressing as an isolated behaviour. Blanchard proposed that this erotic orientation drives one of two clinically distinguishable pathways to a male-to-female transsexual identity, the other being associated with early-onset gender dysphoria and same-sex attraction. The distinction matters because patients presenting through each pathway have different clinical histories, different motivations, and arguably different therapeutic needs. What followed the publication of his research was not ordinary scientific scrutiny. Blanchard describes, and others who engaged with his work confirm, that his typology became the target of sustained activist opposition aimed not at refuting it with contrary evidence but at having it excluded from diagnostic frameworks, removed from teaching, and classified as inherently harmful. His research was cited in major diagnostic manuals but in ways critics argue were deliberately obscured. The episode traces how political pressure on professional bodies can reshape the categories clinicians use — with direct consequences for the patients they treat. These are not abstract methodological disputes. When a clinically validated distinction between patient populations is suppressed, practitioners lose the conceptual tools needed to ask relevant questions, take accurate histories, or give patients a genuinely informed picture of what may be driving their distress. If Blanchard's typology has merit — and it has been independently examined and partially replicated — then its marginalisation represents a cost borne not by ideologues but by patients who were assessed and treated without reference to available evidence. The relevance for European health systems is direct. The systematic reviews commissioned in England, Sweden, Finland, and Norway between 2019 and 2024 each identified clinical practice that had outrun its evidence base, in some cases by decades. Blanchard's story illuminates part of the mechanism by which that happened: when organised pressure succeeds in removing inconvenient research from professional discourse, guidelines fill with consensus rather than evidence, and patients are harmed by what practitioners were trained not to know. Restoring the evidence base in gender medicine means reckoning with what was deliberately set aside — and why.
